Investing
Regeneron preliminary Q4 US sales of Eylea below expectations
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron (NASDAQ:) Pharmaceuticals on Monday reported eye drug Eylea’s fourth-quarter U.S. preliminary sales, which came below Wall Street expectations, as the company’s blockbuster product faced pressure from a rival.
The company garnered $1.34 billion in U.S. sales, while Wells Fargo analyst Mohit Bansal last week pegged consensus Wall Street estimates for U.S. sales of Eylea at $1.53 billion.
Eylea, jointly developed with Bayer AG (ETR:), has driven Regeneron’s earnings for years, but its sales have come under pressure, partly from Roche’s Vabysmo that secured U.S. approval in 2022.
Regeneron has set its hopes on a higher-dose version of Eylea. U.S. sales of the version came in at about $123 million in the quarter, the company said. (This story has been corrected to say Roche’s Vabysmo was approved in 2022, not last year, in paragraph 3)
Read the full article here
VP Exec’s Top Tips for Negotiating and Relationship-Building
Why the Smallest Details Mean the Most in Marketing
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
How Sustainable Business Practices Can Drive Global Success
Britain’s FTSE 100 rises as oil price jump boosts energy shares By Reuters
3 Steps You Can’t Miss When Growing Your Business
Here’s the Typical American’s Income at Every Age. How Do You Compare?
How I Transformed My Business by Letting Go of Low-Value Tasks
Germany stocks lower at close of trade; DAX down 0.65% By Investing.com
How to Develop Empowered Leaders Within Your Own Team
Debt ceiling debate and its effect on the U.S. dollar
Debt ceiling default: Still no deal between parties
Stovall: If the U.S. defaults on its debt, all S&P 500 sectors will likely fall
What China's weaker-than-expected economy could mean for U.S. markets
A ‘Big Short’ investor sees financial disaster brewing in housing markets — again
-
Side Hustles7 days ago3 Steps You Can’t Miss When Growing Your Business
-
Make Money7 days agoHere’s the Typical American’s Income at Every Age. How Do You Compare?
-
Investing7 days agoHow I Transformed My Business by Letting Go of Low-Value Tasks
-
Investing7 days agoGermany stocks lower at close of trade; DAX down 0.65% By Investing.com
-
Side Hustles6 days agoHow to Develop Empowered Leaders Within Your Own Team
-
Side Hustles5 days agoHow Your Body Language Can Help Win a Disagreement
-
Side Hustles4 days agoHow to Be Unapologetically You and Why It Matters
-
Passive Income5 days agoAre You Running Your Business, or Is Your Business Running You?